Key Insights The current range of weight-loss drugs on the market targets GLP-1 receptors. Seeking a new generation of weight-loss drugs, some companies are developing amylin analogs. As clinical trial data around amylin analogs emerge, investors worry about the amount of weight loss the molecules can offer. For the past 7 years, pharmaceuticals that work as glucagon-like peptide 1 (GLP-1) receptor agonists have dominated the weight-loss and diabetes markets. These drugs, currently sold by Novo Nordisk […]

Read more

New research from 23and ME sheds a light on why GLP-1 weight-loss drugs work differently across patients, with two studies suggesting that genetic variation and cardiovascular mechanisms independent of weight loss may both play significant roles in determining individual outcomes. Emerging Pharma Leaders nominations are now open! Do you know someone who can make tough decisions that continue to face manufacturers? Are they destined to change the future of pharma? Nominate a colleague with impressive leadership and […]

Read more

Transcript Keith Baar, PhD: Hi there, I’m Professor Keith Barr. I’m a professor of molecular exercise physiology at the University of California Davis, and my colleague here is Henning Langer. Henning Langer, PhD: And I am a biologist focusing on skin and muscle wasting at the Charité Berlin. And we are particularly interested in the effect of GLP-1 medicines and their effect on skin and muscle. Keith Baar, PhD: Perfect, and so our latest study showed that […]

Read more

Weight loss drugs containing GLP-1 agonists have exploded in popularity in recent years, gaining the interest of consumers for usage far beyond the FDA-approved purpose to treat type 2 diabetes and obesity. This widespread and off-label interest in weight loss drugs has also led to an explosion of unapproved products available online and via social media, which do come with safety risks for consumers. While GLP-1s are currently permitted in sport, it’s important for athletes to know […]

Read more

Glucagon-like peptide-1 agonism – GLP-1, common in obesity medicines – is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences. This research represents a potential alternative obesity treatment, as it could make peptide-containing medicines more tolerable and easier to employ for a large pool of patients by eliminating unfavorable gastrointestinal side effects. In a report published in Molecular Metabolism in April 2026, DiMarchi […]

Read more

Medi-Weightloss, which offers medically supervised weight loss programs, opened a Georgetown clinic in early April. The gist Services available include GLP-1 medications, diabetes treatment, IV therapy, vitamin and nutrient injections, and more. The location offers a free in-person health assessment with no commitment required. Owner Shankar Bellam said patients describe the team as encouraging and investing in real, lasting results—not just the number on the scale. Medi-Weightloss has 136 locations nationwide, including another Central Texas clinic in […]

Read more

Basically, your plate can look just as full, but it’s built around foods with higher water and fiber content—like soups, fruits, vegetables, beans, yogurt, oats, stews—rather than filled with calorie-dense options, brownies, chips, high-fat cheeses, and spreads like peanut butter. A 2025 study in the American Journal of Clinical Nutrition similarly suggests that when people eat primarily whole or minimally processed foods, they can often consume a larger volume while taking in fewer calories than on an […]

Read more